Cantor Fitzgerald Reaffirms Their Buy Rating on TherapeuticsMD (TXMD)


Cantor Fitzgerald analyst William Tanner maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) today and set a price target of $26. The company’s shares opened today at $5.19.

Tanner commented:

“We view TXMD as being well-positioned to launch important therapies for menopause-associated conditions. FDA approval of Imvexxy (fka TX-004) positions the company well, in our view to bring an important new therapy to the market for treating vulvar vaginal atrophy (VVA). The balance of 2018 is populated with important events including the expectation for Imvexxy launch in 2H18 and an October 28 PDUFA data for TX-001.”

According to TipRanks.com, Tanner is a 2-star analyst with an average return of 1.2% and a 41.8% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Intra-Cellular Therapies.

TherapeuticsMD has an analyst consensus of Strong Buy, with a price target consensus of $17.25, representing a 232.4% upside. In a report issued on July 30, Oppenheimer also reiterated a Buy rating on the stock with a $12 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.66 and a one-year low of $4.34. Currently, TherapeuticsMD has an average volume of 3.15M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.

Read More on TXMD:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts